VCYT
Veracyte, Inc. NASDAQ Listed Oct 30, 2013$41.19
Mkt Cap $3.3B
52w Low $22.61
66.1% of range
52w High $50.71
50d MA $33.30
200d MA $35.62
P/E (TTM)
39.4x
EV/EBITDA
33.3x
P/B
2.0x
Debt/Equity
0.0x
ROE
5.1%
P/FCF
26.1x
RSI (14)
—
ATR (14)
—
Beta
1.96
50d MA
$33.30
200d MA
$35.62
Avg Volume
905.1K
About
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic S…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.34 | 0.36 | +5.9% | 32.97 | +18.3% | +24.9% | — | — | — | — | — |
| Feb 25, 2026 | AMC | 0.41 | 0.53 | +29.8% | 35.72 | +7.8% | +8.5% | +2.4% | +0.8% | -1.8% | +1.5% | — |
| Nov 4, 2025 | AMC | 0.32 | 0.51 | +59.4% | 36.12 | +10.7% | +27.5% | +15.4% | +15.4% | +17.2% | +18.1% | — |
| Aug 6, 2025 | AMC | 0.31 | 0.44 | +41.9% | 23.97 | +8.5% | +15.5% | +14.2% | +16.8% | +20.0% | +28.0% | — |
| May 7, 2025 | AMC | 0.20 | 0.31 | +55.0% | 30.84 | -2.1% | +1.2% | -3.7% | -0.3% | -5.0% | -7.6% | — |
| Feb 24, 2025 | AMC | 0.10 | 0.36 | +260.0% | 39.36 | -8.3% | -15.0% | -9.7% | -14.0% | -11.7% | -14.7% | — |
| Nov 6, 2024 | AMC | 0.03 | 0.19 | +603.7% | 36.59 | +8.5% | +2.0% | -0.3% | +6.3% | +4.5% | +8.0% | — |
| Aug 6, 2024 | AMC | 0.05 | 0.30 | +530.7% | 21.82 | +20.1% | +24.0% | +37.4% | +34.1% | +37.1% | +49.2% | — |
| May 7, 2024 | AMC | -0.19 | -0.02 | +89.5% | 21.03 | +3.1% | -4.3% | -1.9% | +1.6% | +7.0% | +9.5% | — |
| Feb 22, 2024 | AMC | -0.07 | -0.04 | +42.9% | 24.34 | -2.2% | -8.9% | -3.2% | -3.0% | -2.3% | -3.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Canaccord Genuity | Maintains | Hold → Hold | — | $33.80 | $33.35 | -1.3% | -1.0% | -0.9% | -0.3% | -1.9% | +1.6% |
| Apr 1 | Needham | Maintains | Buy → Buy | — | $32.21 | $32.31 | +0.3% | +0.6% | +0.1% | +0.3% | -0.2% | +1.4% |
| Mar 30 | Guggenheim | Maintains | Buy → Buy | — | $30.01 | $30.20 | +0.6% | +1.4% | +7.3% | +8.0% | +7.5% | +7.7% |
| Mar 6 | Morgan Stanley | Maintains | Underweight → Underweight | — | $34.68 | $33.34 | -3.9% | -2.4% | -3.8% | -5.5% | -6.4% | -10.8% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $35.72 | $38.51 | +7.8% | +8.5% | +2.4% | +0.8% | -1.8% | +1.5% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $42.39 | $42.41 | +0.0% | +2.9% | +7.7% | +6.4% | +2.8% | -0.8% |
| Dec 2 | Morgan Stanley | Maintains | Underweight → Underweight | — | $46.39 | $46.25 | -0.3% | -0.5% | +2.9% | +2.2% | -3.8% | -4.4% |
| Nov 11 | Morgan Stanley | Maintains | Underweight → Underweight | — | $42.35 | $42.44 | +0.2% | +0.7% | -0.1% | -5.9% | -7.1% | -7.2% |
| Nov 5 | UBS | Maintains | Buy → Buy | — | $36.12 | $40.00 | +10.7% | +27.5% | +15.4% | +15.4% | +17.2% | +18.1% |
| Nov 5 | Canaccord Genuity | Maintains | Hold → Hold | — | $36.12 | $40.00 | +10.7% | +27.5% | +15.4% | +15.4% | +17.2% | +18.1% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Leadership transitions with equity incentives can signal confidence in succession planning, but investors should monitor whether new executives meet performance targets to ensure shareholder value isn't diluted through excessive equity grants.
Mar 16
8-K
Veracyte, Inc. -- 8-K Filing
Veracyte's fourth quarter testing revenue grew 21% to $135.8 million, demonstrating strong operational momentum in its diagnostic testing business.
Feb 25
Data updated apr 27, 2026 7:27am
· Source: massive.com